Fadi G Hage1,2, Gopal Ghimire3, Davis Lester4, Joshua Mckay3, Steven Bleich3, Stephanie El-Hajj5, Ami E Iskandrian3. 1. Department of Medicine, University of Alabama at Birmingham, Lyons Harrison Research Building 314, 1900 University BLVD, Birmingham, AL, 35294, USA. fadihage@uab.edu. 2. Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA. fadihage@uab.edu. 3. Department of Medicine, University of Alabama at Birmingham, Lyons Harrison Research Building 314, 1900 University BLVD, Birmingham, AL, 35294, USA. 4. School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 5. Department of Medicine, Louisiana State University, Baton Rouge, LA, USA.
Abstract
BACKGROUND: Regadenoson (REGA), a selective adenosine A2A receptor agonist, is the most widely used stress agent for SPECT myocardial perfusion imaging (MPI) in the United States. The diagnostic accuracy of REGA MPI is comparable to Adenosine MPI, but its prognostic value is not well defined. METHODS: We categorized 1,400 patients (700 consecutive normal and 700 consecutive abnormal REGA-MPIs) into 4 groups based on the perfusion defect size using automated quantitative analysis: Group 1: normal perfusion; Group 2: <10% of left ventricle; Group 3: 10%-20%; Group 4: >20%. The primary outcome was a composite of cardiac death, myocardial infarction (MI), and late coronary revascularization (CR >90 days after MPI). RESULTS: Of the 1,400 patients (42% male, 37% diabetes, 21% heart failure, 26% end-stage renal disease), the primary outcome occurred in 23% (17% cardiac death, 4% MI, 6% late CR) during 46 ± 18 months of follow-up and 8% had early CR (within 90 days of MPI). Early CR occurred in 0.4%, 9%, 17%, and 17% and the primary outcome in 10%, 27%, 31%, and 43% in Groups 1-4, respectively (P < .001 for both). In an adjusted Cox proportional model, the hazard ratio for the primary outcome was 2.68 (1.77-4.06), 3.32 (2.28-4.83), and 4.05 (2.78-5.91) for Groups 2-4 compared to Group 1. CONCLUSION: REGA MPI provides powerful prognostic information that has important implications in patient management and can guide clinical practice.
BACKGROUND:Regadenoson (REGA), a selective adenosine A2A receptor agonist, is the most widely used stress agent for SPECT myocardial perfusion imaging (MPI) in the United States. The diagnostic accuracy of REGA MPI is comparable to Adenosine MPI, but its prognostic value is not well defined. METHODS: We categorized 1,400 patients (700 consecutive normal and 700 consecutive abnormal REGA-MPIs) into 4 groups based on the perfusion defect size using automated quantitative analysis: Group 1: normal perfusion; Group 2: <10% of left ventricle; Group 3: 10%-20%; Group 4: >20%. The primary outcome was a composite of cardiac death, myocardial infarction (MI), and late coronary revascularization (CR >90 days after MPI). RESULTS: Of the 1,400 patients (42% male, 37% diabetes, 21% heart failure, 26% end-stage renal disease), the primary outcome occurred in 23% (17% cardiac death, 4% MI, 6% late CR) during 46 ± 18 months of follow-up and 8% had early CR (within 90 days of MPI). Early CR occurred in 0.4%, 9%, 17%, and 17% and the primary outcome in 10%, 27%, 31%, and 43% in Groups 1-4, respectively (P < .001 for both). In an adjusted Cox proportional model, the hazard ratio for the primary outcome was 2.68 (1.77-4.06), 3.32 (2.28-4.83), and 4.05 (2.78-5.91) for Groups 2-4 compared to Group 1. CONCLUSION:REGA MPI provides powerful prognostic information that has important implications in patient management and can guide clinical practice.
Authors: Hsiao D Lieu; John C Shryock; Gregory O von Mering; Toufigh Gordi; Brent Blackburn; Ann W Olmsted; Luiz Belardinelli; Richard A Kerensky Journal: J Nucl Cardiol Date: 2007-07 Impact factor: 5.952
Authors: G Germano; H Kiat; P B Kavanagh; M Moriel; M Mazzanti; H T Su; K F Van Train; D S Berman Journal: J Nucl Med Date: 1995-11 Impact factor: 10.057
Authors: Rory Hachamovitch; Sean W Hayes; John D Friedman; Ishac Cohen; Daniel S Berman Journal: J Am Coll Cardiol Date: 2005-03-01 Impact factor: 24.094
Authors: R Hachamovitch; D S Berman; H Kiat; I Cohen; H Lewin; A Amanullah; X Kang; J Friedman; G A Diamond Journal: Am J Cardiol Date: 1997-08-15 Impact factor: 2.778
Authors: Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang Journal: J Nucl Cardiol Date: 2007 Sep-Oct Impact factor: 5.952
Authors: A M Amanullah; D S Berman; J Erel; H Kiat; I Cohen; G Germano; J D Friedman; R Hachamovitch Journal: Am J Cardiol Date: 1998-09-15 Impact factor: 2.778
Authors: Christopher W Ives; Wael A AlJaroudi; Vineeta Kumar; Ayman Farag; Dana V Rizk; Suzanne Oparil; Ami E Iskandrian; Fadi G Hage Journal: Eur J Nucl Med Mol Imaging Date: 2018-06-07 Impact factor: 9.236